Hookipa Pharma (HOOK) AI Stock Analysis

• Market Cap: $15.07M
• Dividend Yield: N/A
• Average Volume (3M): 59.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: 118.32%
• EPS Growth: 61.16%
• Country: US
• Employees: 179
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -3.55
• Shares Outstanding: 9,659,522
• 10 Day Avg. Volume: 70,719
• 30 Day Avg. Volume: 59,546
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.34
• Price to Cash Flow (P/CF): -0.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 70.94% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3

Hookipa Pharma's overall stock score reflects significant financial instability, with zero revenue in 2024 and persistent losses. Technical analysis indicates bearish momentum, and valuation metrics are weak due to negative earnings. These factors underscore the company's need for strategic adjustments to improve financial health and investor confidence.

Positive Factors

Clinical Trials

The combination of eseba-vec and Keytruda continues to show beneficial responses in first-line head-and-neck cancer, supporting a Market Outperform rating for Hookipa Pharma.

Financial Performance

Hookipa reported 3Q results demonstrating the impact of its cost-cutting efforts, beating consensus estimates.

Negative Factors

Pipeline Development

Uncertainty regarding Hookipa’s pipeline development and a near-term dilution risk has led to a downgrade of HOOK to Neutral from Buy.

Shareholder Impact

Current Hookipa shareholders are expected to face significant dilution.

Hookipa Pharma Business Overview & Revenue Model

Company Description

HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.

How the Company Makes Money

Hookipa Pharma generates revenue through strategic collaborations, partnerships, and research grants that support the development of its immunotherapy pipeline. These collaborations often involve upfront payments, milestone payments, and royalties on product sales if the treatments are successfully commercialized. Additionally, the company may receive government or institutional grants to fund specific research initiatives. As a clinical-stage company, Hookipa currently does not generate revenue from product sales, as its therapies are still under development and not yet approved for commercial use.

Hookipa Pharma Financial Statement Overview

Summary

Hookipa Pharma faces substantial financial difficulties with zero revenue in 2024 and persistent losses. While leverage risk is low due to minimal debt, declining equity and cash flow challenges raise concerns over long-term financial health.

Income Statement

Hookipa Pharma's income statement reveals a challenging financial performance with zero revenue in 2024, a significant decline from previous years. The gross profit margin is non-existent, and they have substantial negative EBIT and EBITDA margins. The net profit margin is also negative, reflecting ongoing losses. Revenue growth has been inconsistent, with a notable drop in the most recent year. The company's trajectory indicates financial instability and a need for strategic adjustments to improve revenue streams.

Balance Sheet

The balance sheet of Hookipa Pharma shows a moderate level of financial stability. The debt-to-equity ratio is low due to minimal debt, indicating low leverage risk. However, the return on equity is negative, driven by consecutive net losses. The equity ratio is satisfactory, suggesting a capital structure with a higher proportion of equity funding. Despite the low debt levels, the declining equity value and recurring losses raise concerns about long-term solvency and the need for improved operational performance.

Cash Flow

Cash flow analysis highlights significant challenges, with negative operating and free cash flows in 2024, further deteriorating from the previous year. The free cash flow to net income ratio and operating cash flow to net income ratio are adverse, reflecting cash outflows exceeding earnings. The free cash flow growth rate is negative, indicating a need for better cash management and operational efficiency. Overall, cash flow constraints pose a risk to sustaining operations without fresh capital infusions.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	20.13M	14.25M	18.45M	19.58M
	Gross Profit
0.00	16.58M	10.65M	13.81M	-33.55M
	EBIT
-51.45M	-97.69M	-73.16M	-81.67M	-53.28M
	EBITDA
-51.45M	-77.34M	-60.40M	-70.13M	-39.15M
	Net Income Common Stockholders
-43.50M	-81.58M	-64.92M	-75.67M	-44.08M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
39.68M	117.10M	113.44M	66.91M	143.18M
	Total Assets
82.55M	161.34M	170.45M	126.05M	187.82M
	Total Debt
875.00K	6.56M	6.50M	10.63M	10.51M
	Net Debt
-38.81M	-110.54M	-106.94M	-56.29M	-132.67M
	Total Liabilities
31.33M	71.48M	67.94M	36.45M	31.69M
	Stockholders Equity
51.21M	89.86M	102.52M	89.59M	156.12M
Cash Flow		Free Cash Flow
-76.98M	-61.68M	-25.01M	-78.60M	-41.71M
	Operating Cash Flow
-76.98M	-57.52M	-20.00M	-66.02M	-39.34M
	Investing Cash Flow
-194.00K	-4.16M	-5.02M	-12.58M	-2.37M
	Financing Cash Flow
-1.28M	65.67M	72.27M	-235.00K	73.42M

Hookipa Pharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.17
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HOOK, the sentiment is Negative. The current price of 1.17 is below the 20-day moving average (MA) of 1.52, below the 50-day MA of 1.77, and below the 200-day MA of 3.99, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 28.60 is Positive, neither overbought nor oversold. The STOCH value of 13.92 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HOOK.

Hookipa Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONC	56 Neutral	$27.60B	―	-18.77%	―	54.96%	27.51%
Sector *	49 Neutral	$6.84B	0.05	-53.14%	2.48%	24.49%	-3.26%
IOVA	48 Neutral	$1.25B	―	-57.48%	―	13698.99%	31.46%
ADAP	44 Neutral	$118.14M	―	-53.54%	―	145.37%	57.01%
KPTI	41 Neutral	$63.37M	―	41.08%	―	-0.55%	49.85%
HOOK	34 Underperform	$15.07M	―	-61.68%	―	118.32%	61.16%

Hookipa Pharma Corporate Events

Hookipa Pharma Seeks Validation for Stockholder Meetings

HOOKIPA Pharma Inc. filed a petition in the Delaware Court of Chancery on December 27, 2024, to validate actions taken during its 2022 and 2023 Annual Stockholder Meetings. These actions include the approval of director elections and amendments to the company’s certificate of incorporation and stock option plan. The company is seeking validation due to incorrect record dates set for these meetings, which contravened the Delaware General Corporation Law. The Court of Chancery has approved an expedited proceeding, with a final hearing scheduled for February 14, 2025, where stockholders can express their positions.